Qiagen NV (QGEN)
42.28
-0.35
(-0.82%)
USD |
NYSE |
Nov 14, 12:17
Qiagen Net Income (Quarterly): -183.46M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -183.46M |
| March 31, 2024 | 80.67M |
| December 31, 2023 | 97.66M |
| September 30, 2023 | 77.82M |
| June 30, 2023 | 80.79M |
| March 31, 2023 | 85.04M |
| December 31, 2022 | 88.84M |
| September 30, 2022 | 82.39M |
| June 30, 2022 | 96.66M |
| March 31, 2022 | 155.31M |
| December 31, 2021 | 129.19M |
| September 30, 2021 | 133.14M |
| June 30, 2021 | 121.05M |
| March 31, 2021 | 129.22M |
| December 31, 2020 | 212.68M |
| September 30, 2020 | 16.91M |
| June 30, 2020 | 89.76M |
| March 31, 2020 | 39.83M |
| December 31, 2019 | 44.93M |
| September 30, 2019 | -160.64M |
| June 30, 2019 | 44.73M |
| March 31, 2019 | 29.52M |
| December 31, 2018 | 60.95M |
| September 30, 2018 | 60.32M |
| June 30, 2018 | 36.82M |
| Date | Value |
|---|---|
| March 31, 2018 | 32.30M |
| December 31, 2017 | -39.69M |
| September 30, 2017 | 48.48M |
| June 30, 2017 | 13.95M |
| March 31, 2017 | 17.65M |
| December 31, 2016 | 8.623M |
| September 30, 2016 | 34.80M |
| June 30, 2016 | 21.27M |
| March 31, 2016 | 15.71M |
| December 31, 2015 | 51.62M |
| September 30, 2015 | 33.93M |
| June 30, 2015 | 25.11M |
| March 31, 2015 | 19.49M |
| December 31, 2014 | 25.57M |
| September 30, 2014 | 34.69M |
| June 30, 2014 | 32.83M |
| March 31, 2014 | 23.27M |
| December 31, 2013 | 60.15M |
| September 30, 2013 | 40.70M |
| June 30, 2013 | -51.76M |
| March 31, 2013 | 19.98M |
| December 31, 2012 | 38.42M |
| September 30, 2012 | 29.16M |
| June 30, 2012 | 33.33M |
| March 31, 2012 | 28.59M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-183.46M
Minimum
Jun 2024
212.68M
Maximum
Dec 2020
83.08M
Average
88.84M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| LENZ Therapeutics Inc | -10.22M |
| Oruka Therapeutics Inc | -- |
| Boston Scientific Corp | 468.00M |
| uniQure NV | -44.38M |
| ProQR Therapeutics NV | -2.899M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 496.35M |
| Total Expenses (Quarterly) | 656.70M |
| EPS Diluted (Quarterly) | -0.83 |
| Enterprise Value | 9.986B |
| Gross Profit Margin (Quarterly) | 7.00% |
| Profit Margin (Quarterly) | -36.96% |
| Earnings Yield | 0.75% |
| Operating Earnings Yield | 1.76% |
| Normalized Earnings Yield | 1.550 |